| Citation: |
CHEN W L, FU J Q, ZHU C Y, et al. Preliminary analysis of association of m7G methyltransferase 1 with pan-cancer prognosis and immune infiltration[J]. Journal of Guangxi medical university, 2024, X(X): 1-8. DOI：.
|
To investigate the expression of RNA m7G methyltransferase 1 (METTL1) in various types of tumors and its association with prognosis and immune infiltration, in order to provide a new reference for the screening of cancer biomarkers and their mechanisms of occurrence and development.
The Cancer Genome Atlas (TCGA) was used to analyze the mRNA expression profile of METTL1 in 33 tumors and the differences in METTL1 expression between the tumor group and the normal control group. Cox regression model and Kaplan-Meier were used to analyze the correlation between METTL1 expression and the prognosis of cancer patients. The association between METTL1 expression and immune infiltration in liver hepatocellular carcinoma (LIHC) was analyzed, and the mRNA expression levels of METTL1 and immune checkpoint in normal hepatocytes and LIHC cells were preliminatively verified by fluorescence quantitative PCR.
The expression level of METTL1 was different between cancer tissues and adjacent tissues, and it was highly expressed in most cancer tissues. High expression of METTL1 significantly shortened the median survival time of patients with low grade glioma (LGG), LIHC and mesothelioma (MESO). The expression level of METTL1 in LIHC was positively correlated with the levels of multiple inflammatory cells. And the expression level of METTL1 was positively correlated with immune checkpoints LAG3 and PDCD1 (P＜0.001), which was consistent with the mRNA expression level in cultured LIHC cells in vitro.
METTL1 significantly promotes the occurrence and progression of most tumors, negatively regulates the prognosis survival rate of LGG, LIHC and MESO patients, and is positively correlated with immune infiltration. METTL1 is expected to be a cancer biomarker based on LAG3 and PDCD1 immunotherapy.
| [1] |
ZHANG L, CHEN J, MA J N, et al. HN-CNN: a heterogeneous network based on convolutional neural network for m7 G site disease association prediction[J]. Frontiers in genetics, 2021, 12: 655284. doi: 10.3389/fgene.2021.655284
|
| [2] |
LI J Z, WANG L F, HAHN Q, et al. Structural basis of regulated m7G tRNA modification by METTL1-WDR4[J]. Nature, 2023, 613(7943): 391-397. doi: 10.1038/s41586-022-05566-4
|
| [3] |
LIN S B, LIU Q, LELYVELD V S, et al. Mettl1/Wdr4-mediated m7G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation[J]. Molecular cell, 2018, 71(2): 244-255. e5.
|
| [4] |
CHENG W L, GAO A L, LIN H, et al. Novel roles of METTL1/WDR4 in tumor via m7G methylation[J]. Molecular therapy oncolytics, 2022, 26: 27-34. doi: 10.1016/j.omto.2022.05.009
|
| [5] |
KATSARA O, SCHNEIDER R J. m7G tRNA modification reveals new secrets in the translational regulation of cancer development[J]. Molecular cell, 2021, 81(16): 3243-3245. doi: 10.1016/j.molcel.2021.07.030
|
| [6] |
DAI Z H, LIU H N, LIAO J B, et al. N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression[J]. Molecular cell, 2021, 81(16): 3339-3355. e8.
|
| [7] |
DENG Y J, ZHOU Z Y, JI W D, et al. METTL1-mediated m7G methylation maintains pluripotency in human stem cells and limits mesoderm differentiation and vascular development[J]. Stem cell research & therapy, 2020, 11(1): 306.
|
| [8] |
Pan-cancer analysis of whole genomes [J]. Nature, 2020, 578(7793): 82-93.
|
| [9] |
GOLDMAN M J, CRAFT B, HASTIE M, et al. Visualizing and interpreting cancer genomics data via the Xena platform[J]. NATURE BIOTECHNOLOGY, 2020, 38(6): 675-678. doi: 10.1038/s41587-020-0546-8
|
| [10] |
LI T W, FU J X, ZENG Z X, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic acids research, 2020, 48(W1): W509-W514. doi: 10.1093/nar/gkaa407
|
| [11] |
JIN C H, ZHU X D, HUANG X N, et al. Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis[J]. Journal of comparative effectiveness research, 2022, 11(3): 203-212. doi: 10.2217/cer-2021-0134
|
| [12] |
RODRÍGUEZ-GUILARTE L, RAMÍREZ M A, ANDRADE C A, et al. LAG-3 contribution to T cell downmodulation during acute respiratory viral infections[J]. Viruses, 2023, 15(1): 147. doi: 10.3390/v15010147
|
| [13] |
TAWBI H A, SCHADENDORF D, LIPSON E J, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma[J]. The New England journal of medicine, 2022, 386(1): 24-34. doi: 10.1056/NEJMoa2109970
|
| [14] |
LIAO J B, YI Y, YUE X, et al. Methyltransferase 1 is required for nonhomologous end-joining repair and renders hepatocellular carcinoma resistant to radiotherapy[J]. Hepatology, 2023, 77(6): 1896-1910. doi: 10.1002/hep.32615
|
| [15] |
GARCÍA-VÍLCHEZ R, AÑAZCO-GUENKOVA A M, DIETMANN S, et al. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer[J]. Molecular cancer, 2023, 22(1): 119. doi: 10.1186/s12943-023-01809-8
|
| [16] |
WANG C, WANG W, HAN X D, et al. Methyltransferase-like 1 regulates lung adenocarcinoma A549 cell proliferation and autophagy via the AKT/mTORC1 signaling pathway[J]. Oncology letters, 2021, 21(4): 330. doi: 10.3892/ol.2021.12591
|
| [17] |
JIANG H X, LIU Y, SONG H B, et al. METTL1 promotes colorectal cancer cell proliferation by attenuating CHEK2-induced G1/S phase arrest[J]. Genes & diseases, 2024, 11(2): 579-581.
|
| [18] |
ZENG X Z, LIAO G R, LI S M, et al. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation[J]. Hepatology, 2023, 77(4): 1122-1138. doi: 10.1002/hep.32585
|
| [19] |
XU F S, CAI D R, LIU S S, et al. N7-methylguanosine regulatory genes well represented by METTL1 define vastly different prognostic, immune and therapy landscapes in adrenocortical carcinoma[J]. American journal of cancer research, 2023, 13(2): 538-568.
|
| [20] |
QI Y N, LIU Z, HONG L L, et al. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting[J]. Journal of hematology & oncology, 2023, 16(1): 89.
|
| [21] |
WANG Z T, DENG Z M, DAI F F, et al. Tumor immunity: a brief overview of tumor-infiltrating immune cells and research advances into tumor-infiltrating lymphocytes in gynecological malignancies (Review)[J]. Experimental and therapeutic medicine, 2024, 27(4): 166. doi: 10.3892/etm.2024.12453
|
| [22] |
MARCISCANO A E, ANANDASABAPATHY N. The role of dendritic cells in cancer and anti-tumor immunity[J]. Seminars in immunology, 2021, 52: 101481. doi: 10.1016/j.smim.2021.101481
|
| [23] |
SHI N, ZHOU Y, LIU Y J, et al. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy[J]. Frontiers in immunology, 2022, 13: 1047610. doi: 10.3389/fimmu.2022.1047610
|
| [24] |
LECOCQ Q, KEYAERTS M, DEVOOGDT N, et al. The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time’s a charm[J]. International journal of molecular sciences, 2020, 22(1): 75. doi: 10.3390/ijms22010075
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: